Neuroaid (also NeuroAiD, MLC 601, or MLC 901) is a claimed treatment for stroke sold by Moleac Pte Ltd, a biopharmaceutical company in Singapore. There are two versions: Neuroaid (MLC601) and Neuroaid II (MLC901), with differing blends of ingredients. The ingredients total 14 for both, with nine derived from plants and five from animals.
Mechanisms of action
In vitro and in vivo results show that Neuroaid makes cells more resistant against glutamate aggression, increases neurite outgrowth and connectivity as well as reduces the infarct volume.
There is weak evidence that Neuroaid (MLC 601) might have some benefit for post-stroke recovery when used in addition to standard treatment.
^ abHeurteaux C, Gandin C, Borsotto M, et al. (June 2010). "Neuroprotective and neuroproliferative activities of NeuroAid (MLC601, MLC901), a Chinese medicine, in vitro and in vivo". Neuropharmacology58 (7): 987–1001. doi:10.1016/j.neuropharm.2010.01.001. PMID20064536.
^Broussalis E, Trinka E, Killer M, Harrer A, McCoy M, Kraus J (2012). "Current therapies in ischemic stroke. Part B. Future candidates in stroke therapy and experimental studies". Drug Discov Today17 (13-14): 671–84. doi:10.1016/j.drudis.2012.02.011. PMID22405898.
^Siddiqui, Fahad Javaid; Venketasubramanian, Narayanaswamy; Chan, Edwin Shih-Yen; Chen, Christopher (2013). "Efficacy and Safety of MLC601 (NeuroAiD®), a Traditional Chinese Medicine, in Poststroke Recovery: A Systematic Review". Cerebrovascular Diseases35: 8–17. doi:10.1159/000346231. PMID23548914.